Background: The use of point-of-care (POC) tests prior to the COVID-19 pandemic was relatively infrequent outside of the health care context. Little is known about how public opinions regarding POC tests have changed during the pandemic.
Methods: We redeployed a validated survey to uncompensated volunteers to assess preferences for point-of-care testing (POCT) benefits and concerns between June and September 2022. We received a total of 292 completed surveys. Linear regression analysis was used to compare differences in survey average response scores (ARSs) from 2020 to 2022.
Results: Respondent ARSs indicated agreement for all 16 POCT benefits in 2022. Of 14 POCT concerns, there were only 2 statements that respondents agreed with most frequently, which were that "Insurance might not cover the costs of the POC test" (ARS 0.9, ± 1.0) and "POC tests might not provide a definitive result" (ARS 0.1, ± 1.0). Additionally, when comparing survey responses from 2020 to 2022, we observed 8 significant trends for POCT harms and benefits.
Conclusion: The public's opinion on POC tests has become more favorable over time. However, concerns regarding the affordability and reliability of POCT results persist. We suggest that stakeholders address these concerns by developing accurate POC tests that continue to improve care and facilitate access to health care for all.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11232423 | PMC |
| http://dx.doi.org/10.1016/j.cvdhj.2024.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quantitative determination of leptin hormone using gold nanoparticle-based lateral flow assay.
Mikrochim Acta
January 2025
Science and Technology Research and Application Center (BITAM), Necmettin Erbakan University, Konya, Türkiye.
A lateral flow assay (LFA) has been developed that can be used in point-of-care (PoC) use for the sensitive determination of leptin hormone. The limit of detection value was 0.158 ng/mL and the limit of quantification value was 0.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Burke Neurological Institute, Weill Cornell Medicine, White Plains, NY, USA.
Background: Benfotiamine, a prodrug of thiamine, raises blood levels by 50-100 times to achieve pharmacologic effects. It provides a novel therapeutic direction addressing a well-characterized brain tissue thiamine deficiency and related changes in glucose metabolism in AD. BenfoTeam is a seamless phase 2A-2B "proof of concept" (POC), double-blind, placebo-controlled RCT investigating tolerability, safety, and efficacy of benfotiamine, as a first-in-class small molecule treatment for early AD.
View Article and Find Full Text PDFComparison between point-of-care testing from capillary samples and conventional laboratory testing from venous samples for white blood cells and C-reactive protein in a pediatric outpatient setting.
J Gen Fam Med
January 2025
Department of Pediatrics Tsugaruhoken Medical COOP Kensei Hospital Hirosaki Aomori Japan.
Background: Studies on the accuracy of point-of-care (POC) testing using capillary samples are scarce. Therefore, this study aimed to assess the analytical accuracy of POC testing for white blood cell (WBC) and C-reactive protein (CRP) using capillary samples compared with conventional central laboratory testing using venous samples in a pediatric ambulatory care setting.
Methods: This was a retrospective study including patients younger than 18 years who underwent concurrent WBC and CRP evaluations via capillary and subsequent venous sampling within a 2-h window.
Embryoscopy and targeted embryo biopsy for the management of early abortion.
J Assist Reprod Genet
January 2025
Centro de Asistencia a La Reproducción Humana de Canarias, La Laguna, Santa Cruz de Tenerife, Spain.
Purpose: To evaluate the safety, accuracy, and effectiveness of embryoscopy for the management of early abortion and to test the hypothesis that targeted embryo and chorionic villi sampling avoids maternal cell contamination (MCC) for genetic testing of products of conception (POC).
Methods: This ambispective study included 74 consecutive patients presenting with early abortion. Gestations between 5 and 9 weeks, obtained either spontaneously or through assisted reproductive technologies were included.
Community pharmacies: Key players in point-of-care diagnostics for STI screening in Africa.
PLoS One
January 2025
Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Background: Sexually Transmitted Infections (STIs) rank in the top 5 disease categories for which adults in developing countries seek healthcare services. Community pharmacies offer clients convenience, proximity, extended opening hours, privacy, and efficiency, which could make them desirable locations for HIV and STI screening and treatment. We examined the feasibility of using point-of-care (POC) STI tests for screening HIV and other STIs at community pharmacies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!